Immix Biopharma (NASDAQ:IMMX – Get Free Report) posted its earnings results on Friday. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $12.14. Bank of America initiated coverage on Immix Biopharma in a research report on Thursday, June 18th. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy. Further ReadingReceive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.